CD34 and acute myeloid leukemia: In this chapter we will focus on outcomes of HCT using T cell depletion for the treatment of AML in recipients of matched or partially mismatched donors (7/8 or 8/8 HLA-matched), with a primary focus on ex vivo CD34+ selection of the graft.